Angioplasty for acute coronary syndromes in the era of the stent

: Pharmacological treatment frequently stabilizes symptoms of patients with acute myocardial ischemia. However, significant quiescent residual stenosis normally persists and leads to rethrombosis. Since rethrombosis produces reischemia and has a deleterious impact on initial and long-term prognosis in these patients, definitive normalisation of local flow assured through deactivation treatments and complete passivation of quiescent residual stenosis in an inert plaque should be a main priority in modern treatment of acute coronary ischemia. Considering the negative influence of significant stenosis on rethrombosis, and that the normalization has a clear antithrombotic effect of flow, routine elimination of residual stenosis by means of angioplasty should prevent rethrombosis and its side effects. Nevertheless, according to trials carried out previous to the most relevant progresses in the field of interventional cardiology, the advantage of this strategy over the conservative treatment has not been clearly demonstrated. Coronary stenting produces a real normalisation of flow and lumen which prevents local thrombosis. In concordance with these facts, recent evidence indicates a substancial clinical benefit of stenting in very thrombogenic acute settings, such as primary angioplasty or refractory acute coronary angina. Presumably, routine stenting also benefits initial and long-term prognosis of other subsets of unstable patients, especially those with thrombolysed myocardial infarction and stabilized patients with acute ischemia without ST-segment elevation. To demonstrate this new trials are needed to compare the efficacy of conservative and interventional approaches that incorporate the advances of each strategys. Until new data are available on these studies, the treatment of acute coronary ischemia should be tailored to each patient and no out-dated recommendation should be given or accepted.